Showing 2691-2700 of 4166 results for "".
- Imprimis Announces Clinical Trial for Dropless TriMoxi Formulation in Canadahttps://modernod.com/news/imprimis-announces-clinical-trial-for-dropless-trimoxi-formulation-in-canada/2479968/Imprimis Pharmaceuticals announced that its Canadian partner, Advanced Dosage Forms, will begin enrolling patients at McGill University Health Centre (MUHC) for a clinical trial of Imprimis’s leading Dropless (triamcinolone acetonide-moxifloxacin) formulation aft
- Lenstec Receives FDA Approval for the SBL-3 Multifocal IOLhttps://modernod.com/news/lenstec-receives-fda-approval-for-sbl-3-multifocal-iol/2481002/Lenstec Announced that its SBL-3 IOL has been approved by the FDA. The SBL-3 IOL (Segmented Bifocal Lens) is a next-generation asymmetric multifocal refractive IOL that provides patients with near, intermediate and distance vision. Its patented design allows for improved contrast sensit
- Lenstec Completes FDA Trial for SBL-3 IOLhttps://modernod.com/news/lenstec-completes-fda-trial-for-sbl-3-iol/2476837/Lenstec announced that it has completed its FDA trial for the SBL-3 IOL (Segmented Bifocal Lens), an asymmetric multifocal refractive IOL designed to provide patients with superior near, intermediate, and distance vision. It also offers improved contrast sensitivity and minimizes halos and glare
- Lenstec Completes Enrollment of FDA Trial for SBL-3 IOLhttps://modernod.com/news/lenstec-completes-enrollment-of-fda-trial-for-sbl-3-iol/2479919/Lenstec announced that it has completed enrollment of the FDA trial for the SBL-3 IOL. The Lenstec SBL-3 IOL (segmented bifocal lens) is a non-concentric asymmetric multifocal refractive IOL that provides patients with superior near, intermediate, and distance vision. It also improves contrast se
- Study: Specialized Smart Soft Contact Lenses Can Address Global Issue of Glaucoma Diagnosis, Managementhttps://modernod.com/news/study-specialized-smart-soft-contact-lenses-can-address-global-issue-of-glaucoma-diagnosis-management/2481144/The vision of
- OliX Pharmaceuticals Doses First Patient in Clinical Trial for RNAi Therapeutic OLX10212 for Dry and Wet AMDhttps://modernod.com/news/olix-pharmaceuticals-doses-first-patient-in-clinical-trial-for-rnai-therapeutic-olx10212-for-dry-and-wet-amd/2481494/OliX Pharmaceuticals announced that the first patient has been successfully dosed in a phase 1 clinical trial (
- RG6501 (OpRegen) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summithttps://modernod.com/news/rg6501-opregen-phase-12a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit/2481476/Lineage Cell Therapeutics announced that results from a phase 1/2a clinical study of RG6501 (OpRegen), will be presented at the
- Nicox to Receive Milestone Payments from Kowa as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japanhttps://modernod.com/news/nicox-to-receive-milestone-payments-from-kowa-as-ncx-470-prepares-to-enter-phase-3-clinical-trials-in-japan/2482819/Nicox SA announced that its exclusive Japanese partner for NCX 470, Kowa, has received Clinical Trial Notification (equivalent of a US Investigational New Drug, IND) approval to initiate phase 3 clinical trials on NCX 470 for the treatment of ocular hypertension in Ja
- Ocugen Doses First Patient in Phase 3 Clinical Trial for OCU400 Gene Therapy for RPhttps://modernod.com/news/ocugen-doses-first-patient-in-phase-3-clinical-trial-for-ocu400-gene-therapy-for-retinitis-pigmentosa/2482326/Ocugen announced that the first patient has been dosed in its phase 3 liMeliGhT clinical trial for OCU400, a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP). “Each clinical milestone achieved by OCU400 brings us closer to providing a one-
- Azura Ophthalmics Enrolls First Patient in Phase 3 Clinical Trial for AZR-MD-001 in Patients with MGDhttps://modernod.com/news/azura-ophthalmics-enrolls-first-patient-in-phase-3-clinical-trial-for-azr-md-001-in-patients-with-mgd/2482307/Azura Ophthalmics announced that the first patient has been enrolled in the ASTRO study—a phase 3 clinical trial assessing the efficacy and safety of AZR-MD-001 in patients with clinical signs and symptoms of meibomian gland dysfunction (MGD). "AZR-MD-001 has already dem